Stock Market Warning: Consumer Confidence Plunged
Stock markets once again proved that they are pricing in problems ahead. On Tuesday, the Conference Board’s Consumer Confidence Index reported a significant decline. Tariff threats, which lead to an increasingly isolated U.S., hurt sentiment.The index read was 98.3, down from 105 in January. Economists expected a 102.5 reading. The confidence reading is now down three months in a row. What is worse is that the average 12-month inflation expectation increased to 6% in February, up from 5.2%.Investors exposed to consumer spending should hold consumer defensive stocks. Procter & Gamble (PG) and Johnson & Johnson (JNJ) traded near 52-week highs. Ahead of the economic data, investors increased positions in those firms. Similarly, Kraft Heinz (KHC), Mondelez (MDLZ), and Hershey Company (HSY) rebounded. Stagflation RisksStagflation risks are rising. Inflation will likely continue, especially after the U.S. imposes tariffs on its key trade partners. The U.S. economy may slow as countries decide to do less business with Americans. Stock markets, which briefly touched all-time highs, are losing momentum. The recent streak of the index closing lower is a troubling sign. Neutral markets may turn into bearish ones. Nasdaq (QQQ) is due for correction, too. In Tuesday’s stock market, Nvidia (NVDA), Tesla (TSLA), AMD (AMD), and Dell Technologies (DELL) closed lower.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


